From heart to brain: cognitive potential of propranolol and diltiazem through cholinergic enhancement via butyrylcholinesterase inhibition
Propranolol and diltiazem demonstrate selective BChE inhibition, with propranolol showing potency comparable to established potent BChE inhibitors. Given their established safety profiles and CNS activity, these compounds represent promising candidates for repurposing in the treatment of AD and other cognitive disorders. Further <i>in vivo</i> studies are warranted to explore their therapeutic potential.
Authors
- Rajnish Kumar (ORCID: https://orcid.org/0000-0002-7021-6996)
- Amit Kumar (ORCID: https://orcid.org/0000-0001-7669-0712)
- Taher Darreh‐Shori (ORCID: https://orcid.org/0000-0003-1176-6258)
- Celtia Domínguez-Fernández (ORCID: https://orcid.org/0000-0002-0668-4672)
Institutions
- Karolinska Institutet (SE)
- Indian Institute of Technology BHU (IN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3389/fphar.2025.1694610
- Primary Topic
- Cholinesterase and Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00